Emavusertib - Aurigene Oncology/Curis
Alternative Names: AU 4948; CA 4948Latest Information Update: 06 Jun 2024
At a glance
- Originator Aurigene Discovery Technologies
- Developer Curis; University of Leipzig
- Class Amides; Amines; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Oxazoles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Clk dual-specificity kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia
- Phase I/II Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Phase I Gastric cancer; Oesophageal cancer
- Preclinical Adenocarcinoma; Rheumatoid arthritis
Most Recent Events
- 05 Jun 2024 National Cancer Institute plans a phase I trial for Urogenital cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) (PO), in August 2024 (NCT06439836)
- 31 May 2024 Pharmacodynamics data from a phase I/IIa trial in Myelodysplastic neoplasms (MDS) and Acute myeloid leukemia (AML) presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Updated efficacy and adverse events results from a pase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)